Cluster for Individualized ImmuneIntervention (Ci3)
e. V.

© Ci3 – Cluster for Individualized ImmuneIntervention (Ci3) e. V.

Innovation in Individualized Medicine

The Cluster for Individualized Immune Intervention (Ci3) e.V. is a non-profit organization that aims to promote the advancement of personalized medicine and individualized immunotherapies for the treatment of serious diseases such as cancer. By facilitating collaboration between academia, small and medium-sized enterprises, large corporations, regulators and the public, Ci3 contributes to the development and establishment of innovative solutions in the healthcare sector benefiting all healthcare stakeholders (patients, payers, providers and manufacturers). Bundling the outstanding expertise in the Rhine-Main region in individualized medicine and establishing the region as a global leader in the field is central to our strategy.

Ci3 is headquartered in the Rhine-Main region, one of the world’s leading pharmaceutical and life science regions and home to more than 300 healthcare and biotech companies, including renowned corporations such as Abbott, Boehringer Ingelheim, BioNTech SE, Biotest, Fresenius SE, Merck Serono and Sanofi-Aventis.

In 2012, Ci3 was designated as a „Leading Edge Cluster” in the area of individualized immunotherapies by the German Federal Ministry of Education and Research. As part of the Leading Edge Cluster initiative, 33 projects received funding from the German Federal Government and industry. All projects were successfully completed no later than 2017.

Furthermore, Ci3 plays a leading role in different projects at the national and European levels such as the EU INNOSUP Horizon projects PERMIDES and DIGI-B-CUBE as well as the Health Axis Europe Partnering project (HAEP), which is funded by the German Federal Ministry of Education and Research. These projects aim at advancing innovations in individualized medicine by bringing together relevant stakeholders in the field.